BR112021019479A2 - Prescrição de gerenciamento de paciente remoto com base em biomarcadores - Google Patents
Prescrição de gerenciamento de paciente remoto com base em biomarcadoresInfo
- Publication number
- BR112021019479A2 BR112021019479A2 BR112021019479A BR112021019479A BR112021019479A2 BR 112021019479 A2 BR112021019479 A2 BR 112021019479A2 BR 112021019479 A BR112021019479 A BR 112021019479A BR 112021019479 A BR112021019479 A BR 112021019479A BR 112021019479 A2 BR112021019479 A2 BR 112021019479A2
- Authority
- BR
- Brazil
- Prior art keywords
- biomarker
- patient management
- remote patient
- level
- patient
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Peptides Or Proteins (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166382.2A EP3715851A1 (en) | 2019-03-29 | 2019-03-29 | Prescription of remote patient management based on biomarkers |
| EP19166425 | 2019-03-29 | ||
| EP19175720 | 2019-05-21 | ||
| PCT/EP2020/058700 WO2020201078A1 (en) | 2019-03-29 | 2020-03-27 | Prescription of remote patient management based on biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019479A2 true BR112021019479A2 (pt) | 2021-11-30 |
Family
ID=69941398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019479A BR112021019479A2 (pt) | 2019-03-29 | 2020-03-27 | Prescrição de gerenciamento de paciente remoto com base em biomarcadores |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12442825B2 (https=) |
| EP (1) | EP3948301A1 (https=) |
| JP (2) | JP7575400B2 (https=) |
| CN (1) | CN113348368A (https=) |
| AU (1) | AU2020253042B2 (https=) |
| BR (1) | BR112021019479A2 (https=) |
| CA (3) | CA3281050A1 (https=) |
| WO (1) | WO2020201078A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11783944B2 (en) * | 2019-09-09 | 2023-10-10 | Neal F. Krouse | System for live monitoring of vitals for patients and physicians |
| WO2022101937A1 (en) * | 2020-11-12 | 2022-05-19 | Shah Komal | An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure |
| WO2022164724A1 (en) * | 2021-01-27 | 2022-08-04 | Verantos, Inc. | High validity real-world evidence study with deep phenotyping |
| WO2022245405A1 (en) | 2021-05-17 | 2022-11-24 | Verantos, Inc. | System and method for term disambiguation |
| US20240120105A1 (en) * | 2022-10-09 | 2024-04-11 | Morteza Naghavi | Predicting adverse health risk based on ct scan images and ai-enabled cardiovascular structure volumetry |
| WO2025097159A1 (en) * | 2023-11-05 | 2025-05-08 | 3Ive Labs, Llc | Urinary oxygen and uses thereof in adaptive therapies for kidney function |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943918A (en) | 1971-12-02 | 1976-03-16 | Tel-Pac, Inc. | Disposable physiological telemetric device |
| US4121573A (en) | 1973-10-04 | 1978-10-24 | Goebel Fixture Co. | Wireless cardiac monitoring system and electrode-transmitter therefor |
| FR2570703B1 (fr) | 1984-09-26 | 1988-07-08 | Commissariat Energie Atomique | Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents |
| US4827943A (en) | 1986-09-23 | 1989-05-09 | Advanced Medical Technologies, Inc. | Portable, multi-channel, physiological data monitoring system |
| US4784162A (en) | 1986-09-23 | 1988-11-15 | Advanced Medical Technologies | Portable, multi-channel, physiological data monitoring system |
| US4882733A (en) | 1987-03-13 | 1989-11-21 | Ford Aerospace Corporation | Method and apparatus for combining encoding and modulation |
| US5511553A (en) | 1989-02-15 | 1996-04-30 | Segalowitz; Jacob | Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously |
| US5307818A (en) | 1989-02-15 | 1994-05-03 | Jacob Segalowitz | Wireless electrocardiographic and monitoring system and wireless electrode assemblies for same |
| US4981141A (en) | 1989-02-15 | 1991-01-01 | Jacob Segalowitz | Wireless electrocardiographic monitoring system |
| US5168874A (en) | 1989-02-15 | 1992-12-08 | Jacob Segalowitz | Wireless electrode structure for use in patient monitoring system |
| FR2664699B1 (fr) | 1990-07-13 | 1995-08-18 | Cis Bio Int | Procede d'amplification du signal d'emission d'un compose luminescent. |
| US5353793A (en) | 1991-11-25 | 1994-10-11 | Oishi-Kogyo Company | Sensor apparatus |
| US5214939A (en) | 1991-11-25 | 1993-06-01 | Carrier Corporation | Variable area refrigerant expansion device having a flexible orifice |
| ES2155068T3 (es) | 1992-04-03 | 2001-05-01 | Micromedical Ind Ltd | Sistema de supervision fisiologica. |
| US5522396A (en) | 1992-05-12 | 1996-06-04 | Cardiac Telecom Corporation | Method and system for monitoring the heart of a patient |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US5544661A (en) | 1994-01-13 | 1996-08-13 | Charles L. Davis | Real time ambulatory patient monitor |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| US6416471B1 (en) | 1999-04-15 | 2002-07-09 | Nexan Limited | Portable remote patient telemonitoring system |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| DE102007022367A1 (de) | 2007-05-07 | 2008-11-20 | B.R.A.H.M.S Ag | Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten |
| EP2107377A1 (en) * | 2008-04-04 | 2009-10-07 | BRAHMS Aktiengesellschaft | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
| CN105044349B (zh) * | 2010-08-26 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
| CN108931658A (zh) * | 2018-04-16 | 2018-12-04 | 上海交通大学医学院附属瑞金医院 | 用于诊断心力衰竭合并症及预后评估的血清标记物 |
-
2020
- 2020-03-27 WO PCT/EP2020/058700 patent/WO2020201078A1/en not_active Ceased
- 2020-03-27 CA CA3281050A patent/CA3281050A1/en active Pending
- 2020-03-27 BR BR112021019479A patent/BR112021019479A2/pt unknown
- 2020-03-27 AU AU2020253042A patent/AU2020253042B2/en active Active
- 2020-03-27 US US17/599,157 patent/US12442825B2/en active Active
- 2020-03-27 CN CN202080010888.0A patent/CN113348368A/zh active Pending
- 2020-03-27 CA CA3281038A patent/CA3281038A1/en active Pending
- 2020-03-27 CA CA3124744A patent/CA3124744A1/en active Pending
- 2020-03-27 JP JP2021556866A patent/JP7575400B2/ja active Active
- 2020-03-27 EP EP20713309.1A patent/EP3948301A1/en active Pending
-
2024
- 2024-10-17 JP JP2024181851A patent/JP2025015545A/ja active Pending
-
2025
- 2025-06-25 US US19/248,953 patent/US20250369987A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3281050A1 (en) | 2026-03-02 |
| CN113348368A (zh) | 2021-09-03 |
| US20220260589A1 (en) | 2022-08-18 |
| CA3281038A1 (en) | 2026-03-02 |
| JP7575400B2 (ja) | 2024-10-29 |
| AU2020253042A1 (en) | 2021-06-17 |
| CA3124744A1 (en) | 2020-10-08 |
| AU2020253042B2 (en) | 2025-10-02 |
| US20250369987A1 (en) | 2025-12-04 |
| JP2025015545A (ja) | 2025-01-30 |
| WO2020201078A1 (en) | 2020-10-08 |
| US12442825B2 (en) | 2025-10-14 |
| JP2022526507A (ja) | 2022-05-25 |
| EP3948301A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019479A2 (pt) | Prescrição de gerenciamento de paciente remoto com base em biomarcadores | |
| Yu et al. | What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS) | |
| Sun et al. | Controlling Nutritional Status (CONUT) score as a predictor of all-cause mortality in elderly hypertensive patients: a prospective follow-up study | |
| Dieplinger et al. | Soluble ST2 in heart failure | |
| Rhodes et al. | Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension | |
| Parissis et al. | Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels | |
| Bayes-Genis et al. | Multiple biomarker strategies for risk stratification in heart failure | |
| Wright et al. | Presence and characterisation of anaemia in diabetic foot ulceration | |
| Pérez-Navero et al. | Cardiac biomarkers of low cardiac output syndrome in the postoperative period after congenital heart disease surgery in children | |
| BRPI0922052A2 (pt) | Método para determinar o risco de pré-eclâmpsia usando os marcadores pigf-2 e pigf-3 | |
| Lauque et al. | Predictive Value of the Heart‐type Fatty Acid–binding Protein and the Pulmonary Embolism Severity Index in Patients With Acute Pulmonary Embolism in the Emergency Department | |
| Hage et al. | Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study | |
| BR112018073214A2 (pt) | métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador | |
| Bernardes et al. | Myocardial perfusion in rheumatoid arthritis patients: associations with traditional risk factors and novel biomarkers | |
| Grandi et al. | Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease | |
| Canney et al. | Glomerular filtration rate-specific cutoffs can refine the prognostic value of circulating cardiac biomarkers in advanced chronic kidney disease | |
| Jiang et al. | Erythrocyte transfusion limits the role of elevated red cell distribution width on predicting cardiac surgery associated acute kidney injury | |
| Hesselink et al. | NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk | |
| Montazer et al. | Prognostic value of cardiac troponin I and T on admission in mortality of multiple trauma patients admitted to the emergency department: a prospective follow-up study | |
| Sutaria et al. | Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease | |
| Myhre et al. | Performance of a novel research-use-only secretoneurin ELISA in patients with suspected acute coronary syndrome: comparison with an established secretoneurin radioimmunoassay | |
| US20160356789A1 (en) | Method of Detection of Summed Cardiac Troponins for Cardiovascular Risk Stratification | |
| Deng et al. | Serum N-terminal pro-B-type natriuretic peptide and cystatin C for acute kidney injury detection in critically ill adults in China: a prospective, observational study | |
| Hong et al. | Preoperative prealbumin does not impact outcomes after left ventricular assist device implantation | |
| Carro | Nutritional status in advanced heart failure and heart transplant patients |